Kangyuan Pharmaceutical (600557.SH) has received the approval notice for the clinical trial of KYS2301 gel.

Translated to China Fortune Financial News App News, Kangyuan Pharmaceutical (600557.SH) announced that the company recently received a Class 1 chemical new drug KYS2301 gel (three specifications) "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, allowing the product to conduct clinical trials for the indication of "atopic dermatitis".